Edition:
India

XBiotech Inc (XBIT.OQ)

XBIT.OQ on NASDAQ Stock Exchange Global Select Market

5.80USD
2:29am IST
Change (% chg)

$-0.30 (-4.92%)
Prev Close
$6.10
Open
$6.15
Day's High
$6.15
Day's Low
$5.41
Volume
39,302
Avg. Vol
24,902
52-wk High
$6.50
52-wk Low
$2.13

Latest Key Developments (Source: Significant Developments)

Xbiotech Says First Audit In New Manufacturing Facility Shows Compliance With Gmp Guidelines
Monday, 3 Dec 2018 

Dec 3 (Reuters) - XBiotech Inc ::XBIOTECH ANNOUNCES SUCCESSFUL COMPLETION OF GMP AUDIT.XBIOTECH INC - RECENTLY RETIRED ITS OLD OPERATIONS, WHICH INCLUDED A GMP MANUFACTURING FACILITY.XBIOTECH INC - FIRST AUDIT IN COMPANY'S NEW MANUFACTURING FACILITY SHOWS COMPLIANCE WITH GMP GUIDELINES.XBIOTECH INC - AUDIT WAS CONDUCTED IN CONNECTION WITH XBIOTECH'S DISTRIBUTION IN EUROPE OF ITS US-MANUFACTURED BIOLOGICAL DRUG PRODUCT.  Full Article

Xbiotech Announces Dismissal Of Securities Class Action Suit
Wednesday, 24 Oct 2018 

XBiotech Inc ::XBIOTECH ANNOUNCES DISMISSAL OF SECURITIES CLASS ACTION SUIT.XBIOTECH INC - JUDGE DUSTIN HOWELL ISSUED LETTER RULING GRANTING CO'S MOTION TO DISMISS SECURITIES CLASS ACTION COMPLAINT BROUGHT AGAINST XBIOTECH.  Full Article

XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology
Monday, 16 Apr 2018 

April 16 (Reuters) - XBiotech Inc ::XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY.XBIOTECH INC - CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO'S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES.XBIOTECH INC - UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS).  Full Article